176 related articles for article (PubMed ID: 25250919)
21. STRIPAK directs PP2A activity toward MAP4K4 to promote oncogenic transformation of human cells.
Kim JW; Berrios C; Kim M; Schade AE; Adelmant G; Yeerna H; Damato E; Iniguez AB; Florens L; Washburn MP; Stegmaier K; Gray NS; Tamayo P; Gjoerup O; Marto JA; DeCaprio J; Hahn WC
Elife; 2020 Jan; 9():. PubMed ID: 31913126
[TBL] [Abstract][Full Text] [Related]
22. EIF5A regulates proliferation and chemoresistance in pancreatic cancer through the sHH signalling pathway.
Wang Z; Jiang J; Qin T; Xiao Y; Han L
J Cell Mol Med; 2019 Apr; 23(4):2678-2688. PubMed ID: 30761741
[TBL] [Abstract][Full Text] [Related]
23. Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells.
Bao B; Wang Z; Ali S; Ahmad A; Azmi AS; Sarkar SH; Banerjee S; Kong D; Li Y; Thakur S; Sarkar FH
Cancer Prev Res (Phila); 2012 Mar; 5(3):355-64. PubMed ID: 22086681
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
[TBL] [Abstract][Full Text] [Related]
25. Overexpressed EDIL3 predicts poor prognosis and promotes anchorage-independent tumor growth in human pancreatic cancer.
Jiang SH; Wang Y; Yang JY; Li J; Feng MX; Wang YH; Yang XM; He P; Tian GA; Zhang XX; Li Q; Cao XY; Huo YM; Yang MW; Fu XL; Li J; Liu DJ; Dai M; Wen SY; Gu JR; Hong J; Hua R; Zhang ZG; Sun YW
Oncotarget; 2016 Jan; 7(4):4226-40. PubMed ID: 26735172
[TBL] [Abstract][Full Text] [Related]
26. CD147 silencing via RNA interference reduces tumor cell invasion, metastasis and increases chemosensitivity in pancreatic cancer cells.
Pan Y; He B; Song G; Bao Q; Tang Z; Tian F; Wang S
Oncol Rep; 2012 Jun; 27(6):2003-9. PubMed ID: 22427101
[TBL] [Abstract][Full Text] [Related]
27. An undesired effect of chemotherapy: gemcitabine promotes pancreatic cancer cell invasiveness through reactive oxygen species-dependent, nuclear factor κB- and hypoxia-inducible factor 1α-mediated up-regulation of CXCR4.
Arora S; Bhardwaj A; Singh S; Srivastava SK; McClellan S; Nirodi CS; Piazza GA; Grizzle WE; Owen LB; Singh AP
J Biol Chem; 2013 Jul; 288(29):21197-21207. PubMed ID: 23740244
[TBL] [Abstract][Full Text] [Related]
28. CXCR4/Let-7a Axis Regulates Metastasis and Chemoresistance of Pancreatic Cancer Cells Through Targeting HMGA2.
Xiao G; Wang X; Yu Y
Cell Physiol Biochem; 2017; 43(2):840-851. PubMed ID: 28954272
[TBL] [Abstract][Full Text] [Related]
29. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
30. miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4.
Zhao G; Wang B; Liu Y; Zhang JG; Deng SC; Qin Q; Tian K; Li X; Zhu S; Niu Y; Gong Q; Wang CY
Mol Cancer Ther; 2013 Nov; 12(11):2569-80. PubMed ID: 24013097
[TBL] [Abstract][Full Text] [Related]
31. Determination of dendritic spine morphology by the striatin scaffold protein STRN4 through interaction with the phosphatase PP2A.
Lin L; Lo LH; Lyu Q; Lai KO
J Biol Chem; 2017 Jun; 292(23):9451-9464. PubMed ID: 28442576
[TBL] [Abstract][Full Text] [Related]
32. High STRN Expression Promotes HCC Invasion and Migration but Not Cell Proliferation or Apoptosis through Facilitating Epithelial-Mesenchymal Transition.
Du QY; Yao JH; Zhou YC; Xu LJ; Zhao FY; Yang Y
Biomed Res Int; 2020; 2020():6152925. PubMed ID: 32280692
[TBL] [Abstract][Full Text] [Related]
33. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
34. Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.
Treviño JG; Verma M; Singh S; Pillai S; Zhang D; Pernazza D; Sebti SM; Lawrence NJ; Centeno BA; Chellappan SP
Mol Cancer Ther; 2013 Dec; 12(12):2722-34. PubMed ID: 24107447
[TBL] [Abstract][Full Text] [Related]
35. Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling.
Xu BQ; Fu ZG; Meng Y; Wu XQ; Wu B; Xu L; Jiang JL; Li L; Chen ZN
Oncotarget; 2016 Sep; 7(38):62177-62193. PubMed ID: 27556697
[TBL] [Abstract][Full Text] [Related]
36. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
37. Mesothelin blockage by Amatuximab suppresses cell invasiveness, enhances gemcitabine sensitivity and regulates cancer cell stemness in mesothelin-positive pancreatic cancer cells.
Matsuzawa F; Kamachi H; Mizukami T; Einama T; Kawamata F; Fujii Y; Fukai M; Kobayashi N; Hatanaka Y; Taketomi A
BMC Cancer; 2021 Feb; 21(1):200. PubMed ID: 33637083
[TBL] [Abstract][Full Text] [Related]
38. Knockdown of Oct4 and Nanog expression inhibits the stemness of pancreatic cancer cells.
Lu Y; Zhu H; Shan H; Lu J; Chang X; Li X; Lu J; Fan X; Zhu S; Wang Y; Guo Q; Wang L; Huang Y; Zhu M; Wang Z
Cancer Lett; 2013 Oct; 340(1):113-23. PubMed ID: 23872274
[TBL] [Abstract][Full Text] [Related]
39. Knockdown of Ezrin by RNA interference reverses malignant behavior of human pancreatic cancer cells in vitro.
Zhong ZQ; Song MM; He Y; Cheng S; Yuan HS
Asian Pac J Cancer Prev; 2012; 13(8):3781-9. PubMed ID: 23098471
[TBL] [Abstract][Full Text] [Related]
40. Silencing of TRPM8 inhibits aggressive tumor phenotypes and enhances gemcitabine sensitivity in pancreatic cancer.
Liu J; Hu G; Gong Y; Yu Q; He B; Li W; He Z; Hao W; He Z; Liu Y
Pancreatology; 2018 Dec; 18(8):935-944. PubMed ID: 30316690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
